Ohio Trasylol® Lawyers

TRASYLOL® SIDE EFFECTS

Schedule a consultation or ask us a free legal question

Study shows drug increases the risk of kidney failure after cardiac artery bypass graft surgery by 259%

A study published by the New England Journal of Medicine in January 2006 shows that Trasylol (generic name aprotinin)

increases the risk of kidney failure

following heart surgery by more than 2 ½ times (259%).

The Food and Drug Administration approved Trasylol for use in the United States in 1993 to control bleeding in patients undergoing open heart surgery and to reduce the need for blood transfusions. The drug works by blocking enzymes that dissolve blood clots.

The study also shows that cheaper alternatives to Trasylol are as effective in limiting blood loss but do not increase the risk of kidney damage.

The manufacturer of the drug, Bayer AG based in Leverkusen, Germany, and its U.S. subsidiary with offices in suburban Pittsburgh, Pennsylvania, insist that the study in the New England Journal is flawed, and that the drug is safe.

The FDA calls the study a "complicated analysis based on a large observational database" and says the agency is working to gather information to evaluate Trasylol's safety.

Many people who were given Trasylol do not know they received it, and medical records need to be reviewed to find out if it was.

We are looking for cases where a person underwent open heart surgery and had kidney problems (with or without dialysis) soon afterward, usually during the same hospitalization when the heart surgery was done. We do not expect you to know whether Trasylol was given.

If you are interested in finding out if Trasylol was given and making a claim against the drug's manufacturer if it was,